Going concern
Filing comparison
Innate Pharma SA disclosed substantial doubt about its ability to continue as a going concern
No going-concern disclosure → Substantial doubt about ability to continue as a going concern
Risks Related to Innate Pharma's Financial Position and Capital Needs The Company's ability to continue as a going concern is subject to its ability to obtain additional financing in the near term. As of December 31, 2025, the Company had cash, cash equivalents, short-term investments and non-current financial assets of €44.8 million, with cash, cash equivalents and short-term investments of €34.3 million. The Company believes its existing cash resources will be sufficient to fund its operations only until the end of the third quarter of 2026. As such, cash and cash equivalents are not…
Evidence
- Blank check
- No
- Comparable
- Yes
- Current state
- substantial_doubt
- Current state label
- Substantial doubt about ability to continue as a going concern
- Direction
- escalated
- Located in
- filing body
- Prior filed
- 2025-04-30
- Prior form
- 20-F
- Prior state
- none
- Prior state label
- No going-concern disclosure
- Source
- ASC 205-40 going-concern note comparison
- Why
- Disclosure about the company's ability to continue as a going concern changed compared with its previous report.